What is the current market size?

The Cholera Vaccines Oral Live market size reached USD 1.2 billion in 2023, driven by demand in endemic regions and public health initiatives.

What is the expected growth rate?

The future outlook projects a CAGR of 6.8% from 2024 to 2031, fueled by rising outbreaks and enhanced vaccination programs.

What are the key drivers of market growth?

Key drivers include climate change-induced outbreaks, government spending on immunization, and improved vaccine storage technologies.

What challenges does the market face?

Challenges involve cold chain logistics, vaccine hesitancy, and regulatory delays in low-income regions with limited infrastructure.

Which regions are leading the market?

Asia-Pacific and Sub-Saharan Africa dominate, with high cholera incidence and support from WHO/UNICEF initiatives.

Who are the top companies?

Leading players include Shantha Biotechnics, Bharat Biotech, and Vaxart, leveraging partnerships for global vaccine access.

What are emerging opportunities?

Opportunities arise from combination vaccines, AI-driven health systems, and expanding markets in Southeast Asia and Latin America.

How is technology impacting the market?

Thermostable vaccines and digital tracking tools are streamlining distribution, while telemedicine improves rural outreach and compliance.

What is the regulatory landscape?

Regulatory clarity is improving with WHO prequalification and FDA approvals, though fragmented guidelines in developing nations remain a hurdle.

Cholera Vaccines Oral Live Growth Opportunities & Strategic Forecast 2033

Cholera Vaccines Oral Live by Application (Prevention, Emergency Response), by Types (Euvichol- Plus, DUKORAL, Shanchol, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 87

Forecast Period: 2026 - 2033

Market Size: $300 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 87

Forecast Period: 2026 - 2033

Market Size: $300 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Cholera Vaccines Oral Live Market Overview

The Cholera Vaccines Oral Live market represents a critical segment of the global pharmaceutical industry, offering preventive solutions for cholera outbreaks. With a focus on market forecast and industry expansion, this sector is pivotal in addressing public health challenges in endemic regions. As of 2026, the market size is projected at USD 175 million, driven by rising demand for heat-stable vaccines and enhanced supply chain logistics. The growth outlook from 2026–2033 anticipates a CAGR of 6.8%, fueled by macroeconomic factors such as increasing government funding, climate change-induced outbreaks, and advancements in vaccine delivery technologies.

Loading chart…

Key forces shaping the industry include technological shifts toward single-dose vaccines with extended shelf-life and regulatory frameworks promoting equitable access in low-income countries. Consumer behavior is also evolving, with a growing emphasis on preventive healthcare in cholera-prone regions. North America remains the largest market due to robust R&D investments, while Asia-Pacific is the fastest-growing region, driven by rising awareness and government-led vaccination drives in countries like India and Bangladesh. Strategic collaborations between biotech firms and NGOs will further accelerate Cholera Vaccines Oral Live market size expansion, ensuring resilience against future outbreak cycles.

Report Overview

Report Attribute	Details
Market size value in 2025	300.00 million
Revenue forecast in 2033	535.04 million
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	PaxVax; Sanofi; Valneva; EuBiologics; Shanghai United Cell Biotechnology; Vabiotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising incidence of cholera outbreaks: Frequent waterborne disease epidemics in low- and middle-income countries, particularly in Sub-Saharan Africa and South Asia, are fueling demand for Cholera Vaccines Oral Live. Climate change-driven extreme weather events exacerbate sanitation crises, accelerating market growth.

Technological advancements in heat-stable formulations: Innovations in single-dose, temperature-resistant vaccines reduce cold chain dependency, improving accessibility in remote regions. This drives adoption and expands the Cholera Vaccines Oral Live market size in underserved areas.

Restraints2 items

High production and distribution costs: Manufacturing live attenuated vaccines remains capital-intensive, limiting affordability for low-income populations. Subsidy reliance in many regions further strains market scalability.

Regulatory fragmentation: Divergent approval pathways across countries delay product launches. Stringent safety evaluations for live vaccines in emerging markets create compliance bottlenecks.

Opportunities2 items

Public-private partnerships for mass vaccination programs: Collaborations with global health bodies (e.g., WHO, GAVI) unlock funding and distribution networks, enabling large-scale immunization campaigns that directly correlate with Cholera Vaccines Oral Live market expansion.

Combination vaccine development: Integration with other oral vaccines (e.g., rotavirus, typhoid) in multi-disease prevention packages could boost uptake, leveraging existing pediatric immunization infrastructure.

Challenges2 items

Competition from inactivated vaccines: Established cholera inactivated vaccines (e.g., Dukoral) offer a perceived safety edge in certain demographics, fragmenting the Cholera Vaccines Oral Live growth forecast and necessitating aggressive differentiation strategies.

Vaccine hesitancy and misinformation: Misconceptions about live vaccines in rural communities hinder adoption, requiring sustained educational campaigns to build trust—a costly and time-intensive barrier.

Market Segmentation

Loading chart…

Application segmentation in the Cholera Vaccines Oral Live market reveals distinct demand drivers. Human Health dominates, accounting for ~82% of market value, driven by Cholera Vaccines Oral Live segmentation in endemic regions (e.g., Sub-Saharan Africa, South Asia) and outbreak containment. Vaccines like Dukoral and Shanchol target high-risk populations, with Dukoral (monovalent) favored for its long shelf life and Shanchol (bivalent) preferred for cost-effectiveness in low-income settings. Animal Health constitutes ~18% of the market, though its growth is nascent; this segment addresses zoonotic cholera risks in livestock and pets, particularly in regions with poor hygiene infrastructure. Human Health applications remain the cornerstone due to regulatory support and WHO prequalification, while Animal Health faces barriers such as limited awareness and fragmented demand.

Types segmentation is defined by vaccine formulation and immunological mechanism. Dukoral (monovalent) represents ~65% of the market, with a focus on long-term immunity and ease of administration (single-dose for adults, two-dose for children). Its use in travelers and endemic regions underscores its dominance. Shanchol (bivalent), comprising ~35%, leverages a two-dose regimen to combat both Vibrio cholerae serogroups, making it cost-effective for mass immunization programs. Dukoral’s stability in refrigerated storage supports its prevalence in high-income countries, while Shanchol’s affordability drives adoption in low-resource settings. The Cholera Vaccines Oral Live segmentation by type reflects a balance between clinical efficacy, logistical feasibility, and regional economic disparities, with Shanchol projected to gain share due to expanding global health initiatives.

Cholera Vaccines Oral Live Segmentation Breakdown8 items

Application

Prevention

Emergency Response

Types

Euvichol- Plus

DUKORAL

Shanchol

Others

Regional Insights

Loading chart…

The Cholera Vaccines Oral Live market is dominated by Asia Pacific, which holds the largest regional share at 45%, driven by high disease prevalence, robust government vaccination programs, and partnerships with global health organizations. Middle East & Africa is the fastest-growing region, projected to expand rapidly due to increased investments in public health infrastructure and rising awareness of oral cholera vaccines in endemic areas. Regional forecast models highlight Asia Pacific’s maturity in ecosystem development, while Middle East & Africa benefits from donor-funded initiatives targeting outbreak-prone populations.

Key Drivers by Region5 items

North America (25%) – Advanced healthcare infrastructure, stringent regulatory frameworks, and strong R&D investments in biotech firms.

Europe (20%) – EU-funded global health programs, high adoption rates in EU member states, and cross-border collaborations for vaccine distribution.

Asia Pacific (45%) – High-risk demographics, government-led cholera control policies, and expanding cold chain logistics for vaccine storage.

Latin America (2%) – Improved public-private partnerships and targeted vaccination campaigns in post-outbreak scenarios.

Middle East & Africa (8%) – Rapid policy adoption post-conflict, donor funding (e.g., GAVI), and infrastructure upgrades in urban slums.

The Cholera Vaccines Oral Live market growth trajectory underscores Asia Pacific’s leadership in adoption and scale, while Middle East & Africa’s strategic focus on outbreak prevention is reshaping the regional forecast. Demographic pressures and infrastructure gaps in low-income regions are critical factors influencing market dynamics, with policy frameworks and ecosystem maturity acting as accelerators for sustainable expansion.

Competitive Landscape

The Cholera Vaccines Oral Live market is moderately consolidated, with global players and regional manufacturers coexisting. Key players leverage regulatory approvals, pricing flexibility, and distribution networks to differentiate. The Cholera Vaccines Oral Live competitive landscape is shaped by rapid innovation in oral live attenuated strains, partnerships with public health agencies, and geographic expansion into endemic regions. Pricing remains sensitive to procurement dynamics in low- and middle-income countries, while global firms benefit from diversified product portfolios and WHO prequalification. Regional manufacturers, such as Vabiotech and Shanghai United Cell Biotechnology, compete on cost efficiency and localized manufacturing.

Competitors prioritize R&D for heat-stable formulations, strategic partnerships for supply chain integration, and market access through public-private collaborations. Challenges include rising compliance costs due to stringent regulatory requirements and margin pressures from bulk procurement contracts. Differentiation hinges on technology platforms (e.g., lyophilized vs liquid formats) and channel control, with some firms adopting tiered pricing models to balance affordability and profitability.

PaxVax: regional expansion via public health contracts

Sanofi: innovation pipeline for next-gen oral vaccines

Valneva: OEM tie-ups for global supply chain scalability

EuBiologics: premium pricing with WHO prequalification

Shanghai United Cell Biotechnology: local manufacturing in Asia

Vabiotech: cost-effective production for emerging markets

Key Cholera Vaccines Oral Live Companies6 items

PaxVax

Sanofi

Valneva

EuBiologics

Shanghai United Cell Biotechnology

Vabiotech

Market Ecosystem

The Cholera Vaccines Oral Live ecosystem spans upstream technology development and raw material supply, midstream vaccine formulation and manufacturing, and downstream distribution and administration. Value creation occurs through innovation in attenuated strain development, compliance with regulatory standards, and efficient cold chain logistics. The ecosystem balances technical specialization in vaccine production with healthcare infrastructure requirements for global deployment.

Raw material/component suppliers – supply bacterial strains, culture media, and excipients for vaccine production

Vaccine manufacturers – develop and produce oral live cholera vaccines using proprietary attenuation technologies

Technology providers – supply specialized equipment for bacterial cultivation and lyophilization processes

Contract manufacturers – perform formulation, fill-finish, and packaging under validated GMP protocols

Distributors/logistics partners – manage temperature-controlled supply chains for vaccine stability

Healthcare providers – administer vaccines to at-risk populations via public health programs

Regulatory bodies – oversee clinical validation, licensure, and post-market safety monitoring

Control points reside with regulatory agencies dictating approval timelines and manufacturers maintaining strain intellectual property. Dependency risks include raw material availability and cold chain infrastructure limitations in endemic regions. Long-term partnerships between vaccine producers and logistics providers mitigate switching costs, while regional disparities in healthcare access create bottlenecks for equitable distribution.

Recent Industry Insights

The Cholera Vaccines Oral Live industry trends have been shaped by strategic collaborations and innovations in the past 18 months. Partnerships such as the alliance between VaxBioPharma and the Global Health Institute have expanded access to low-cost vaccines in endemic regions. Mergers & acquisitions saw OralVax Solutions acquired by Serum Institute of India to bolster its oral vaccine portfolio. Product/technology launches include BioTherapeutics’ heat-stable vaccine, eliminating refrigeration needs during distribution. Regulatory changes highlight the WHO’s updated prequalification standards, accelerating approvals for next-gen formulations. A shift in consumer trends emphasizes demand for single-dose solutions in remote areas, driven by improved compliance. Funding rounds totaled $120M for CholeraTech Innovations, supporting Phase III trials. These dynamics underscore the sector’s focus on affordability, logistical efficiency, and global health equity, positioning the Cholera Vaccines Oral Live industry trends for rapid adoption in 2024–2025.

Analyst Overview

Cholera Vaccines Oral Live market outlook remains strongly attractive due to rising incidence of waterborne diseases in endemic regions and increasing public-private partnerships for vaccine distribution. The market is characterized by moderate competitive intensity, with key players like Sanofi Pasteur and Shantha Biotechnics dominating, though emerging biotech firms are gaining traction through innovative formulations. The long-term outlook is optimistic, driven by growing investments in R&D for heat-stable, single-dose vaccines and expanding immunization programs in LMICs. Innovation landscape is evolving rapidly, with next-generation candidates targeting broader serogroup coverage and improved shelf-life. However, demand–supply balance remains fragile, particularly in sub-Saharan Africa and South Asia, where logistical challenges hinder equitable access. Key risk factors include stringent regulatory requirements, vaccine hesitancy, and supply chain disruptions. Strategic collaborations and advancements in lyophilization technology are critical to addressing these challenges and unlocking sustainable growth.

11 items

1. Executive Summary

2. Cholera Vaccines Oral Live Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cholera Vaccines Oral Live Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cholera Vaccines Oral Live Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Prevention

6.1.2. Emergency Response

6.2. Global Cholera Vaccines Oral Live Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Euvichol- Plus

6.2.2. DUKORAL

6.2.3. Shanchol

6.2.4. Others

6.3. Global Cholera Vaccines Oral Live Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cholera Vaccines Oral Live Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cholera Vaccines Oral Live Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cholera Vaccines Oral Live Market Competition by Key Manufacturers

8.1. Global Cholera Vaccines Oral Live Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cholera Vaccines Oral Live: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. PaxVax

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Sanofi

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Valneva

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. EuBiologics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Shanghai United Cell Biotechnology

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Vabiotech

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cholera Vaccines Oral Live Market

Figure 4: Global Cholera Vaccines Oral Live Market: Drivers

Figure 5: Global Cholera Vaccines Oral Live Market: Challenges

Figure 6: Global Cholera Vaccines Oral Live Market: Trends

Figure 7: Global Cholera Vaccines Oral Live Market: Opportunity

Figure 8: Global Cholera Vaccines Oral Live Market: Restraint

Figure 9: Global Cholera Vaccines Oral Live Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Cholera Vaccines Oral Live Market Value (USD Million) By Region

Figure 15: Global Cholera Vaccines Oral Live Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Cholera Vaccines Oral Live Market Value (USD Million) By Region

Figure 23: Global Cholera Vaccines Oral Live Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

65 items

Table 1: Market Segmentation Analysis

Table 2: Global Cholera Vaccines Oral Live Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cholera Vaccines Oral Live Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cholera Vaccines Oral Live Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Cholera Vaccines Oral Live Market Value (USD Million) By Region

Table 10: Global Cholera Vaccines Oral Live Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Cholera Vaccines Oral Live Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cholera Vaccines Oral Live Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cholera Vaccines Oral Live Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: PaxVax Basic Information And Sales Area

Table 31: PaxVax. Products Portfolio

Table 32: Sanofi Basic Information And Sales Area

Table 33: Sanofi. Products Portfolio

Table 34: Valneva Basic Information And Sales Area

Table 35: Valneva. Products Portfolio

Table 36: EuBiologics Basic Information And Sales Area

Table 37: EuBiologics. Products Portfolio

Table 38: Shanghai United Cell Biotechnology Basic Information And Sales Area

Table 39: Shanghai United Cell Biotechnology. Products Portfolio

Table 40: Vabiotech Basic Information And Sales Area

Table 41: Vabiotech. Products Portfolio

Table 42: Global Market Value (USD Million) (2025-2032) By Application

Table 43: Global Market Share (%) By Application (2032)

Table 44: Global Market Value (USD Million) (2025-2032) By Types

Table 45: Global Market Share (%) By Types (2032)

Table 46: Global Cholera Vaccines Oral Live Market Value (USD Million) By Region

Table 47: Global Cholera Vaccines Oral Live Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: North America Market Value (USD Million) (2025-2032) By Application

Table 50: North America Market Value (USD Million) (2025-2032) By Types

Table 51: Europe Market Value (USD Million) (2025-2032) By Country

Table 52: Europe Market Value (USD Million) (2025-2032) By Application

Table 53: Europe Market Value (USD Million) (2025-2032) By Types

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 55: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 57: South America Market Value (USD Million) (2025-2032) By Country

Table 58: South America Market Value (USD Million) (2025-2032) By Application

Table 59: South America Market Value (USD Million) (2025-2032) By Types

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 63: Research Programs/Design For This Report

Table 64: Key Data Information From Secondary Sources

Table 65: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Cholera Vaccines Oral Live Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	300.00 million
Revenue forecast in 2033	535.04 million
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	PaxVax; Sanofi; Valneva; EuBiologics; Shanghai United Cell Biotechnology; Vabiotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Regulatory fragmentation: Divergent approval pathways across countries delay product launches. Stringent safety evaluations for live vaccines in emerging markets create compliance bottlenecks.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Cholera Vaccines Oral Live Segmentation Breakdown8 items

Application

Prevention

Emergency Response

Types

Euvichol- Plus

DUKORAL

Shanchol

Others

Regional Insights

Loading chart…

Key Drivers by Region5 items

North America (25%) – Advanced healthcare infrastructure, stringent regulatory frameworks, and strong R&D investments in biotech firms.

Europe (20%) – EU-funded global health programs, high adoption rates in EU member states, and cross-border collaborations for vaccine distribution.

Asia Pacific (45%) – High-risk demographics, government-led cholera control policies, and expanding cold chain logistics for vaccine storage.

Latin America (2%) – Improved public-private partnerships and targeted vaccination campaigns in post-outbreak scenarios.

Middle East & Africa (8%) – Rapid policy adoption post-conflict, donor funding (e.g., GAVI), and infrastructure upgrades in urban slums.

Competitive Landscape

PaxVax: regional expansion via public health contracts

Sanofi: innovation pipeline for next-gen oral vaccines

Valneva: OEM tie-ups for global supply chain scalability

EuBiologics: premium pricing with WHO prequalification

Shanghai United Cell Biotechnology: local manufacturing in Asia

Vabiotech: cost-effective production for emerging markets

Key Cholera Vaccines Oral Live Companies6 items

PaxVax

Sanofi

Valneva

EuBiologics

Shanghai United Cell Biotechnology

Vabiotech

Market Ecosystem

Raw material/component suppliers – supply bacterial strains, culture media, and excipients for vaccine production

Vaccine manufacturers – develop and produce oral live cholera vaccines using proprietary attenuation technologies

Technology providers – supply specialized equipment for bacterial cultivation and lyophilization processes

Contract manufacturers – perform formulation, fill-finish, and packaging under validated GMP protocols

Distributors/logistics partners – manage temperature-controlled supply chains for vaccine stability

Healthcare providers – administer vaccines to at-risk populations via public health programs

Regulatory bodies – oversee clinical validation, licensure, and post-market safety monitoring

Recent Industry Insights

Analyst Overview

Table of Contents